Male Breast Cancer Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03018080Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerTreatment